Michael Ehlers will become the chief scientific officer for neuroscience research at drug firm Pfizer in August. He tells Nature why he decided to trade in his post in academia to explore a career in industry.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional information
Interview by Virginia Gewin
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Gewin, V. Michael Ehlers. Nature 466, 401 (2010). https://doi.org/10.1038/nj7304-401a
Published:
Issue date:
DOI: https://doi.org/10.1038/nj7304-401a
